Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis

NCT01242514 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01242514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01242514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
(OSKIRA-X): A Long-term Extension Study to Assess the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Rheumatoid Arthritis
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2011
Completion date
January 31, 2015
Enrollment
1,917 (actual)
Sites
308

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis